Abstract
The novel enterovirus protease inhibitor (PI) SG85 effectively inhibits the in vitro replication of 14 rhinoviruses representative of species A and B (median 50% effective concentration, 0.04 μM). A low-level SG85-resistant variant was selected that carried amino acid substitutions S127G and T143A in the 3C protease. Both substitutions are required for low-level resistance to SG85, as demonstrated by reverse genetics. Interestingly, there is no cross-resistance to SG85 and rupintrivir (another PI); a structural explanation is provided for this observation.
Original language | English |
---|---|
Journal | Antimicrobial Agents and Chemotherapy |
Volume | 59 |
Issue number | 9 |
Pages (from-to) | 5814-5818 |
Number of pages | 5 |
ISSN | 0066-4804 |
DOIs | |
Publication status | Published - 01.09.2015 |